Physician profile
Rajiv Dattatreya
NPI 1801820113
$436,691.25
in general payments reported to CMS, 2019-2025
68 companies · $151K in 2025
The $151K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100K · 2020: $41K · 2021: $39K · 2022: $30K · 2023: $26K · 2024: $50K · 2025: $151K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $194K · Travel and Lodging: $18K · Food and Beverage: $15K · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $194,100.94 |
| Travel and Lodging | $17,661.26 |
| Food and Beverage | $14,812.93 |
| Education | $182.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $141,547.53 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $140,912.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $50,019.39 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $41,457.95 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32,537.93 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals Lp | $9,678.80 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $5,641.94 | 2019-2020 | |
| Abbvie INC. | $3,163.15 | 2019-2025 | Synthroid |
| Merck Sharp & Dohme LLC | $2,239.52 | 2019-2023 | Steglatro |
| Mannkind Corporation | $1,139.70 | 2019-2025 | Afrezza, V-Go |
| Abbott Laboratories | $797.61 | 2020-2025 | Freestyle Libre 3, Alinity |
| Medtronic, INC. | $786.74 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Insulet Corporation | $620.77 | 2019-2025 | Omnipod |
| Dexcom, INC. | $444.43 | 2021-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $367.92 | 2022-2025 | Gvoke Hypopen |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $364.52 | 2019-2025 | Unithroid |
| Radius Health, INC. | $355.44 | 2022-2024 | Tymlos |
| Amarin Pharma, INC. | $299.60 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $259.27 | 2021-2025 | |
| Embecta Corp. | $227.51 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Alexion Pharmaceuticals, INC. | $225.66 | 2022-2025 | Strensiq |
| Averitas Pharma INC. | $213.17 | 2023-2025 | Qutenza |
| Corcept Therapeutics | $211.00 | 2024-2025 | Korlym |
| Pfizer INC. | $209.82 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $187.94 | 2023-2025 | Yorvipath, Skytrofa |
| Becton, Dickinson and Company | $149.74 | 2019-2022 | |
| Cequr Corporation | $141.17 | 2022-2025 | Cequr Simplicity |
| Ibsa Pharma INC. | $140.91 | 2019-2025 | Tirosint, Licart, Flector |
| Ascensia Diabetes Care US INC. | $134.73 | 2021-2024 | |
| Esperion Therapeutics, INC. | $132.15 | 2024 | Nexletol, Nexlizet |
| Tandem Diabetes Care, INC. | $129.99 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $121.63 | 2019-2024 | Xyosted |
| Alvogen INC | $120.35 | 2023-2025 | Teriparatide |
| Boston Scientific Corporation | $104.01 | 2022-2025 | Apollo Esg System |
| Avvisto Therapeutics, LLC | $99.48 | 2024-2025 | Cycloset |
| Recordati_rare_diseases_inc. | $95.87 | 2021-2025 | Isturisa |
| Rhythm Pharmaceuticals, INC. | $93.00 | 2022-2025 | Imcivree |
| Amryt Pharma Holdings Ltd | $91.20 | 2022-2023 | Mycapssa |
| Endo Pharmaceuticals INC. | $87.48 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $84.95 | 2020-2023 | Contrave, Nexletol, Nexlizet |
| Soleno Therapeutics, INC. | $81.54 | 2025 | Vykat Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.69 | 2021-2023 | Cycloset |
| Beta Bionics, INC. | $70.04 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Neurocrine Biosciences, INC. | $62.67 | 2024-2025 | |
| Sequel Med Tech, LLC | $60.56 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $55.82 | 2025 | Rezdiffra |
| Ultragenyx Pharmaceutical INC. | $50.89 | 2020-2021 | |
| Lifescan, INC. | $46.73 | 2022 | |
| Grt US Holding, INC. | $45.27 | 2022 | |
| Zealand Pharma US, INC. | $43.64 | 2022 | |
| Chiesi USA, INC. | $41.84 | 2024-2025 | Mycapssa |
| Shire North American Group INC | $40.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $39.74 | 2021-2022 | |
| Kyowa Kirin, INC. | $38.47 | 2023 | Crysvita |
| Vivus LLC | $36.33 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $33.67 | 2024 | |
| Horizon Therapeutics Plc | $33.33 | 2023 | Tepezza |
| Gilead Sciences, INC. | $31.03 | 2019 | |
| Acerus Pharmaceuticals Corporation | $29.91 | 2020-2022 | |
| Tolmar, INC. | $28.75 | 2025 | Fensolvi |
| Echosens North America, INC. | $19.13 | 2025 | Fibroscan |
| Valeritas, INC. | $17.49 | 2019 | |
| Medtronic Minimed, INC. | $15.96 | 2019 | |
| Renalytix Ai, INC. | $13.60 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Amphastar Pharmaceuticals, INC. | $13.55 | 2025 | |
| Clarus Therapeutics INC. | $12.50 | 2021 | |
| Aytu Biopharma, INC. | $11.68 | 2019 | |
| Althera Pharmaceuticals LLC | $4.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Dattatreya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.